GS
TCON

GTS Securities’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

GTS Securities’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-790
Closed -$2.76K – 4572
2023
Q4 		$2.76K Buy
+790
New +$2.78K ﹤0.01% 3944

Other funds holding TCON

LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

GTS Securities's TCON Position: Q1 2024 in Review

GTS Securities sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q1 2024, closing a stake of 790 shares — an estimated $2.76K sold.

GTS Securities first reported a position in TCON in Q4 2023 and held it in 1 quarter. The position peaked at $2.76K in Q4 2023. 29 funds tracked by Wall St. Rank hold TCON as of Q1 2024.

  • GTS Securities reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • GTS Securities sold 790 TRACON Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $2.76K.
  • GTS Securities first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • GTS Securities's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $2.76K in Q4 2023.
  • 29 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on GTS Securities's 13F filing for Q1 2024, filed 15 May 2024.